company background image

ImpediMed ASX:IPD Stock Report

Last Price


Market Cap







01 Oct, 2022


Company Financials +
IPD fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health5/6

IPD Stock Overview

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.

ImpediMed Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ImpediMed
Historical stock prices
Current Share PriceAU$0.063
52 Week HighAU$0.20
52 Week LowAU$0.049
1 Month Change-1.56%
3 Month Change5.00%
1 Year Change-47.50%
3 Year Change-64.00%
5 Year Change-92.50%
Change since IPO-92.59%

Recent News & Updates

Sep 28
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

IPDAU Medical EquipmentAU Market

Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned -20.8% over the past year.

Return vs Market: IPD underperformed the Australian Market which returned -10.8% over the past year.

Price Volatility

Is IPD's price volatile compared to industry and market?
IPD volatility
IPD Average Weekly Movement15.1%
Medical Equipment Industry Average Movement11.1%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market4.2%

Stable Share Price: IPD is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: IPD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

199973Dave Anderson

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics.

ImpediMed Fundamentals Summary

How do ImpediMed's earnings and revenue compare to its market cap?
IPD fundamental statistics
Market CapAU$112.14m
Earnings (TTM)-AU$19.87m
Revenue (TTM)AU$10.57m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPD income statement (TTM)
Cost of RevenueAU$1.41m
Gross ProfitAU$9.16m
Other ExpensesAU$29.03m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.011
Gross Margin86.66%
Net Profit Margin-188.09%
Debt/Equity Ratio0%

How did IPD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Other financial metrics that can be useful for relative valuation.

IPD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.8x
Enterprise Value/EBITDA-3.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

IPD PS Ratio vs Peers
The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10.3x
EMV EMVision Medical Devices
MX1 Micro-X
CYC Cyclopharm
SOM SomnoMed
IPD ImpediMed

Price-To-Sales vs Peers: IPD is expensive based on its Price-To-Sales Ratio (10.6x) compared to the peer average (10.3x).

Price to Earnings Ratio vs Industry

How does IPD's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (10.6x) compared to the Australian Medical Equipment industry average (7.3x)

Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio38.5x

Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (38.5x).

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IPD (A$0.06) is trading below our estimate of fair value (A$0.81)

Significantly Below Fair Value: IPD is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: IPD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IPD is expected to become profitable in the next 3 years.

Revenue vs Market: IPD's revenue (53.1% per year) is forecast to grow faster than the Australian market (3.7% per year).

High Growth Revenue: IPD's revenue (53.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IPD's Return on Equity is forecast to be low in 3 years time (15.6%).

Discover growth companies

Past Performance

How has ImpediMed performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IPD is currently unprofitable.

Growing Profit Margin: IPD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.

Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-25.3%).

Return on Equity

High ROE: IPD has a negative Return on Equity (-38.94%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is ImpediMed's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IPD's short term assets (A$46.7M) exceed its short term liabilities (A$7.2M).

Long Term Liabilities: IPD's short term assets (A$46.7M) exceed its long term liabilities (A$413.0K).

Debt to Equity History and Analysis

Debt Level: IPD is debt free.

Reducing Debt: IPD has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IPD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is ImpediMed current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

ImpediMed Dividend Yield vs Market
How does ImpediMed dividend yield compare to the market?
SegmentDividend Yield
Company (ImpediMed)n/a
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (ImpediMed)0%

Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IPD has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Dave Anderson (68 yo)





Mr. David W. Anderson, B.S, also known as Dave, serves as Interim Chief Executive Officer of ImpediMed Limited since July 26, 2022. He was Chief Executive Officer of Highmark Western and Northeastern New Y...

Leadership Team

Experienced Management: IPD's management team is considered experienced (3.9 years average tenure).

Board Members

Experienced Board: IPD's board of directors are considered experienced (5.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

ASX:IPD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Jun 22SellAU$935,354Orbis Investment Management LimitedCompany7,118,510AU$0.13
30 Mar 22BuyAU$2,473,438Australian Ethical Investment Ltd.Company16,249,318AU$0.17
18 Nov 21SellAU$348,234Orbis Investment Management LimitedCompany1,917,887AU$0.18
02 Nov 21BuyAU$5,435,855Paradice Investment Management Pty Ltd.Company36,171,104AU$0.15
29 Oct 21SellAU$2,063,032Paradice Investment Management Pty Ltd.Company12,000,000AU$0.18
19 Oct 21BuyAU$397,163Orbis Investment Management LimitedCompany3,177,335AU$0.12
19 Oct 21SellAU$6,384,484Orbis Investment Management LimitedCompany38,285,271AU$0.17

Ownership Breakdown

What is the ownership structure of IPD?
Owner TypeNumber of SharesOwnership Percentage
Private Companies96,733,3545.4%
Individual Insiders124,080,9017.0%
General Public1,203,646,79467.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.

Top Shareholders

Top 25 shareholders own 32.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Paradice Investment Management Pty Ltd.
Australian Ethical Investment Ltd.
Orbis Investment Management Limited
Gregory Brown
39,265,030A$2.5m1.53%no data
MBA Investments Pty Ltd
22,990,990A$1.4m0.86%no data
Sunlora Pty Ltd
21,615,010A$1.4m9.17%no data
Michael Bassett
17,241,008A$1.1m0%no data
Pakasoluto Pty Limited
17,011,421A$1.1m15.72%no data
Hsien Soo
13,852,765A$872.7k38.19%no data
Bsd Pty Ltd
13,000,000A$819.0k6.12%no data
Hme Soo Holdings Pty Ltd
11,913,999A$750.6k0%no data
Stephen Mahnken
10,750,000A$677.3k95.45%no data
Dior Mahnken
10,750,000A$677.3k95.45%no data
Jonnola Pty Ltd
10,201,934A$642.7k13.96%no data
Catherine Kingsford
6,864,910A$432.5k6.84%no data
Richard Carreon
4,104,312A$258.6k0%no data
Donald Williams
3,201,311A$201.7k13.6%no data
Judith Downes
2,874,535A$181.1k6.41%no data
Amit Patel
2,458,251A$154.9k10.07%no data
Dennis Schlaht
2,425,032A$152.8k36.95%no data
Robert Graham
2,193,399A$138.2k7.64%no data
David Adams
1,996,266A$125.8k21.34%no data
Timothy Cruickshank
1,560,258A$98.3k78.86%no data
Shashi Tripathi
1,559,523A$98.2k118.39%no data
Nancy Deisinger
1,512,892A$95.3k47.11%no data

Company Information

ImpediMed Limited's employee growth, exchange listings and data sources

Key Information

  • Name: ImpediMed Limited
  • Ticker: IPD
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: AU$112.139m
  • Shares outstanding: 1.78b
  • Website:

Number of Employees


  • ImpediMed Limited
  • 50 Parker Court
  • Unit 1
  • Pinkenba
  • Queensland
  • 4008
  • Australia


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPDASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2007
IPDQ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2007
IPDCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2007

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.